Andrew A. F. Hack - 03 Nov 2022 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
Director
Signature
/s/ Andrew A. F. Hack
Issuer symbol
NUVL
Transactions as of
03 Nov 2022
Net transactions value
+$4,999,976
Form type
4
Filing time
03 Nov 2022, 16:15:36 UTC
Previous filing
17 Aug 2022
Next filing
08 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVL Class A Common Stock Purchase $4,999,976 +149,253 +4.4% $33.50 3,577,267 03 Nov 2022 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents securities held directly by Bain Capital Life Sciences Fund II, L.P. ("BCLS II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS II and BCLS II Investco, the "Bain Capital Life Sciences Entities").
F2 Bain Capital Life Sciences Investors, LLC ("BCLSI") (i) is the ultimate general partner of each of BCLS II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. As a result, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 On November 3, 2022, BCLS II Investco purchased 149,253 shares of the Issuer's Class A Common Stock at a price of $33.50 per share in an underwritten public offering.